Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (Q33392920)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity |
scientific article |
Statements
1 reference
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (English)
1 reference
Owen A O'Connor
1 reference
Wyndham H Wilson
1 reference
Ann S LaCasce
1 reference
Kieron Dunleavy
1 reference
Myron S Czuczman
1 reference
John F Gerecitano
1 reference
John P Leonard
1 reference
Anil Tulpule
1 reference
Hao Xiong
1 reference
Yi-Lin Chiu
1 reference
Yue Cui
1 reference
Todd Busman
1 reference
Steven W Elmore
1 reference
Saul H Rosenberg
1 reference
Andrew P Krivoshik
1 reference
Sari H Enschede
1 reference
Rod A Humerickhouse
1 reference
18 November 2010
1 reference
1 reference
11
1 reference
12
1 reference
1149-1159
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference